Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

36.30
-0.5400-1.47%
Post-market: 36.360.0600+0.17%19:51 EDT
Volume:6.19M
Turnover:225.49M
Market Cap:26.22B
PE:-77.23
High:37.18
Open:37.03
Low:36.23
Close:36.84
52wk High:37.97
52wk Low:11.60
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.12
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.20
PE(LYR):-67.22

Loading ...

Company Profile

Company Name:
Roivant Sciences Ltd.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
721
Office Location:
50 Broadway,7th Floor,London,Greater London,United Kingdom
Zip Code:
SW1H 0DB
Fax:
- -
Introduction:
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Directors

Name
Position
Matthew Gline
Chief Executive Officer and Director
Daniel Gold
Independent Director
Frank Torti
President and Vant Chair
Ilan Oren
Chair of the Board and Independent Director
James C. Momtazee
Independent Director
Keith Manchester
Independent Director
Mayukh Sukhatme
Director,Chief Investment Officer and President
Meghan FitzGerald
Independent Director
Melissa Epperly
Independent Director

Shareholders

Name
Position
Matthew Gline
Chief Executive Officer and Director
Richard Pulik
Chief Financial Officer
Eric Venker
President and Immunovant CEO
Jennifer Humes
Chief Accounting Officer
Mayukh Sukhatme
Director,Chief Investment Officer and President